Ask AI
ProCE Banner Activity

evERA BC: Phase III Trial of Giredestrant + Everolimus in Advanced ER+/HER2- Breast Cancer Previously Treated With a CDK4/6 Inhibitor

Conference Coverage
Slideset

Primary results from the phase III evERA BC trial showed that the oral SERD giredestrant, in combination with everolimus, improved PFS vs SoC ET plus everolimus in patients with advanced ER-positive/HER2-negative breast cancer who had previously received CDK4/6i therapy. 

Released: October 31, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly